Literature DB >> 10482466

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

K Kondo1, H Ogawa, H Yamashita, H Miyamoto, M Tanaka, K Nakaya, K Kitano, Y Yamamura, S Nakamura, T Onogawa, T Mori, M Tominaga.   

Abstract

We previously reported a series of benzazepine derivatives as orally active nonpeptide arginine vasopressin (AVP) V2 receptor antagonists. After the lead structure OPC-31260 was structurally evaluated and optimized, the introduction of the 7-Cl moiety on the benzazepine and 2-CH3 on the aminobenzoyl moiety enhanced its oral activity. The new AVP-V2 selective antagonist OPC-41061 was determined to be a potent and orally active agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482466     DOI: 10.1016/s0968-0896(99)00101-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.

Authors:  S Nakamura; Y Yamamura; S Itoh; T Hirano; K Tsujimae; M Aoyama; K Kondo; H Ogawa; T Shinohara; K Kan; Y Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; T Mori; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Authors:  Lisa C Costello-Boerrigter; William B Smith; Guido Boerrigter; John Ouyang; Christopher A Zimmer; Cesare Orlandi; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

Review 3.  Vasopressin and vasopressin antagonists in heart failure and hyponatremia.

Authors:  Dimitrios Farmakis; Gerasimos Filippatos; Dimitrios T Kremastinos; Mihai Gheorghiade
Journal:  Curr Heart Fail Rep       Date:  2008-06

4.  Tolvaptan.

Authors:  Jalal K Ghali; Bashar Hamad; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

5.  Recent Advances in the Development of Catalytic Methods that Construct Medium-ring Lactams, Partially Saturated Benzazepines and their Derivatives.

Authors:  Wrickban Mazumdar; Tom G Driver
Journal:  Synthesis (Stuttg)       Date:  2021       Impact factor: 3.157

6.  Methyl 5-chloro-2-[N-(3-eth-oxy-carbonyl-prop-yl)-4-methyl-benzene-sulfonamido]-benzoate.

Authors:  Bin Wang; Ru Jia; Ya-Bin Shi; Fei-Fei He; Hai-Bo Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-26

7.  Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.

Authors:  Savina Nodari; Geoffrey T Jao; Jun R Chiong
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-05-10

8.  Methyl 5-chloro-2-nitro-benzoate.

Authors:  Yan-Shu Liang; Bing-Ni Liu; Mo Liu; Deng-Ke Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-11-02

9.  Conformationally restricted benzothienoazepine respiratory syncytial virus inhibitors: their synthesis, structural analysis and biological activities.

Authors:  Euan A F Fordyce; S Fraser Hunt; Damien Crepin; Stuart T Onions; Guillaume F Parra; Chris J Sleigh; John King-Underwood; Harry Finch; John Murray
Journal:  Medchemcomm       Date:  2018-02-20       Impact factor: 3.597

10.  Modular Entry to Functionalized Tetrahydrobenzo[b]azepines via the Palladium/Norbornene Cooperative Catalysis Enabled by a C7-Modified Norbornene.

Authors:  Xin Liu; Jianchun Wang; Guangbin Dong
Journal:  J Am Chem Soc       Date:  2021-06-23       Impact factor: 16.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.